CFD’er er komplekse instrumenter, og der er en stor risiko forbundet med disse for at miste penge på grund af gearing. 77.3 % af detailinvestorerne har tab på deres konto, når de handler CFD’er med denne udbyder. Du skal overveje, om du forstår, hvordan CFD’er fungerer, og om du har råd til at løbe en stor risiko for at miste dine penge.

Close

Handel Gilead GILD

Gilead live diagram

Grundlæggende Instrumenter

Weekly Search
Weekly
Daily
Dato Luk Ændring % Ændre Åbn Høj Lav

Gilead news

Frances Wang 2024 Aug 04, 16:00

The Week Ahead: ISM services, SMCI

CFD Trading
Magnificent Seven earnings take centre stage in the markets this week
Neil Wilson 2024 Apr 19, 01:00

Week ahead: Wall Street’s Magnificent Seven earnings are up

Commodities Forex Indices Shares
Disney is catching up with Netflix
Neil Wilson 2024 Feb 01, 08:03

Week ahead: Earnings season climax

Forex Indices
Consumer inflation
Neil Wilson 2023 Nov 03, 04:01

Week ahead: RBA poised to hike?

Forex Indices
Megacap-tech-stocks.jpg
Neil Wilson 2023 Apr 21, 05:00

Week ahead: Megacap tech and 1-in-3 Dow components set to report

Seneste nyheder

Vis mere
N/A
Frances Wang 2025 Maj 12, 16:00

ADA crypto price forecast: What factors influence the price of Cardano?

Cryptocurrencies
Tommy Yap 2025 Maj 12, 16:00

Morning Note: Tariff Rollback Sparks Stock Rally; US CPI Watch; Bailey's Speech

Morning Note Equities
Tommy Yap 2025 Maj 12, 04:00

Morning Note: US Surplus Expected; Denmark Inflation; UK Retail Sales Forecast

Morning Note EUR
Frances Wang 2025 Maj 11, 16:00

How the US-China Trade War Influenced Global Commodity Markets?

Commodities
Tommy Yap 2025 Maj 09, 21:00

Week Ahead: U.S. Inflation Data in Spotlight

Forex Indices
Frances Wang 2025 Maj 08, 16:00

What Is Happening to the Bond Market: Bond Market Outlook 2025

Bonds
Frances Wang 2025 Maj 08, 16:00

Bond Market News Today: Alphabet (GOOGL) Back to Corporate Bond Market

Bonds
Frances Wang 2025 Maj 08, 16:00

Tariffs News Update: How Trump’s Policies Affect Bond Market?

Bonds

Info

Spread

0.61

Spread (%)

0.6024 %

Gearing

1:5

Dag til dag-rente Køb

-0.0597 %

Dag til dag-rente Sælg

-0.0292 %

Valuta

USD

Åbningstider for handel

Market lukket

Onsdag

13:31 - 19:59

Mandag

13:31-19:59

Tirsdag

13:31-19:59

Torsdag

13:31-19:59

Fredag

13:31-19:59

Analyse og statistikker

Åbn

---

Forrige luk

---

52 uger høj/lav

--- – ---

Markedsværdi

129255890944

Aktier udestående

1244999936

Indtjeningsdato (Næste)

2013-01-28

Udbytteprocent

2025-06-27

Ex-udbyttedato

2025-06-13

Forventet årlig udbyttesats

3.16

Forventet årlig udbytteprocent

0.0326

EPS

4.76

Få mere at vide om dette instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Relaterede instrumenter

Aktiv
Sælge
Køb
% Ændre
Relaterede instrumenter

latest_education_articles

Vis mere
Trustpilot